Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.

Blood cells

The team has previously shown that development of myofibroblasts, the cells responsible for deposition of the excessive matrix and contraction, is dependent on production of tumour necrosis factor (TNF) by local immune cells. The research, published in PNAS showed that endothelial cells lining the blood vessels modulate the activity of immune regulatory fibroblasts, which secrete mediators that attract the immune cells. They also identified that a potential myofibroblast precursor cell that is contained within a compartment of cells called pericytes that wrap around the blood vessel wall.

First author on the paper, Dr Thomas Layton, who started the work the work as a Kennedy DPhil student at the Kennedy Institute said: "This study illustrates the potential of using state of the art molecular biology techniques to relatively under studied diseases."

Fibrotic diseases, such as idiopathic pulmonary fibrosis, liver cirrhosis and chronic kidney disease, all result from excessive scarring of tissues leading to progressively worsening organ function. Although these diseases have high morbidity and mortality in the Western world, research has been limited by difficulty accessing tissues at the earliest stages of disease. In contrast, in Dupuytren's disease, affected tissues from the palm of the hand are relatively easy to obtain, and can provide clues into fibrotic pathways and possible approaches to slow down or halt disease.

"Animal models fail to recapitulate all aspects of human fibrosis," said Professor Nanchahal. "The pathways we identified using tissue from patients with Dupuytren's disease also appear to pertain to other human fibrotic diseases, such as idiopathic pulmonary fibrosis."

The work was supported by an Oxford-BMS/Celgene fellowship, Royal College of Surgeons of England and British Society for Surgery of the Hand.

Similar stories

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Defining the role of resident memory B cells in the fight against influenza

Researchers at the Kennedy Institute of Rheumatology have used 3D and live-imaging to show how resident memory B cells boost antibodies to fight influenza.

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

The COVID-19 Multi-omic Blood Atlas (COMBAT) has identified blood hallmarks of COVID-19 involving particular immune cell populations and their development, components of innate and adaptive immunity, and connectivity with the inflammatory response.